作者
Arash Kazemi, Jay W McLaren, Casey C Kopczynski, Theresa G Heah, Gary D Novack, Arthur J Sit
发表日期
2018/6/1
期刊
Journal of Ocular Pharmacology and Therapeutics
卷号
34
期号
5
页码范围
380-386
出版商
Mary Ann Liebert, Inc.
简介
Purpose: Netarsudil, an inhibitor of Rho kinase and a norepinephrine transporter, has been shown to lower elevated intraocular pressure (IOP) in controlled studies of patients with open-angle glaucoma and ocular hypertension, and in healthy volunteers. The mechanism of this ocular hypotensive effect in humans is unknown.
Methods: The objective of this study was to evaluate the effect of netarsudil 0.02% on aqueous humor dynamics (AHD) parameters. In this double-masked, vehicle-controlled, paired-eye comparison study, 11 healthy volunteers received topical netarsudil ophthalmic solution 0.02% or its vehicle once daily for 7 days (morning dosing). The primary endpoints were the change in AHD parameters, compared between active and vehicle-treated eyes.
Results: In netarsudil-treated eyes, diurnal outflow facility increased from 0.27 ± 0.10 μL/min/mmHg to 0.33 ± 0.11 μL/min/mmHg (+22%; P …
引用总数
2016201720182019202020212022202320241723192317177
学术搜索中的文章
A Kazemi, JW McLaren, CC Kopczynski, TG Heah… - Journal of Ocular Pharmacology and Therapeutics, 2018